Matinas BioPharma Holdings, Inc.
MTNB
$0.59
-$0.05-7.84%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -99.26% | -80.65% | -65.89% | -42.21% | -21.10% |
| Gross Profit | 99.26% | 80.65% | 65.89% | 42.21% | 14.64% |
| SG&A Expenses | -21.23% | -25.31% | -24.87% | -19.61% | -15.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.48% | -57.30% | -48.65% | -32.71% | -18.91% |
| Operating Income | 65.48% | 57.30% | 48.65% | 32.71% | 15.17% |
| Income Before Tax | 57.48% | 19.81% | 14.07% | 13.29% | -6.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.34% | 20.19% | 14.42% | 13.63% | -5.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.34% | 20.19% | 14.42% | 13.63% | -5.71% |
| EBIT | 65.48% | 57.30% | 48.65% | 32.71% | 15.17% |
| EBITDA | 65.01% | 57.12% | 48.72% | 32.84% | 15.33% |
| EPS Basic | 58.81% | 25.20% | 24.31% | 25.65% | 5.44% |
| Normalized Basic EPS | 67.82% | 59.61% | 52.82% | 40.55% | 21.64% |
| EPS Diluted | 58.81% | 25.20% | 24.31% | 25.65% | 5.44% |
| Normalized Diluted EPS | 67.82% | 59.61% | 52.82% | 40.55% | 21.64% |
| Average Basic Shares Outstanding | 12.50% | 10.58% | 12.62% | 16.21% | 11.96% |
| Average Diluted Shares Outstanding | 12.50% | 10.58% | 12.62% | 16.21% | 11.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |